Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)
Latest Information Update: 24 Feb 2025
At a glance
- Drugs AZD 8630 (Primary) ; AZD 8630 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AstraZeneca
- 22 May 2024 Results of safety of AZD8630 in healthy volunteers and patients with moderate to severe asthma presented at the 120th International Conference of the American Thoracic Society
- 01 May 2024 According to an Amgen Media Release, new respiratory data from this study will be presented at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego.
- 29 Aug 2023 Status changed from active, no longer recruiting to completed.